The polypropylene mesh midurethral sling is the recognized worldwide standard of care for the surgical treatment of stress urinary incontinence. The procedure is safe, effective, and has improved the quality of life for millions of women.''
repairs in a number of areas in the human body and has significantly and favorably impacted the field of hernia surgery. 6, 7 As a knitted implant for the surgical treatment of SUI, macroporous, monofilament, lightweight polypropylene has demonstrated long-term durability, safety, and efficacy up to 17 years. 8 The Monofilament Polypropylene Mesh MUS Is the Most Extensively Studied Anti-Incontinence Procedure in History A broad evidence base including high-quality scientific studies in medical journals in the United States and the world supports the use of the MUS as a treatment of SUI. 9 There are greater than 2000 publications in the scientific literature describing the MUS in the treatment of SUI. These studies include the highest level of scientific evidence in the peer-reviewed scientific literature. 9 The MUS has been studied in virtually all types of patients, with and without comorbidities, and all types of SUI. Multiple randomized controlled trials comparing the types of MUS procedures, and comparing the MUS to other established nonmesh SUI procedures, have consistently demonstrated its clinical effectiveness 9Y12 and patient satisfaction. 12 Among historical SUI procedures, the MUS has been studied as long in follow-up after implantation as any other procedure and has demonstrated superior safety and efficacy. 8 No other surgical treatment of SUI before or since has been subject to such extensive investigation.
Polypropylene Mesh MUSs Are the Standard of Care for the Surgical Treatment of SUI and Represent a Great Advance in the Treatment of This Condition for Our Patients
Since the publication of numerous level 1 randomized comparative trials, the MUS has become the most common surgical procedure for the treatment of SUI in the United States and the developed world. This procedure has essentially replaced open and transvaginal suspension surgeries for uncomplicated SUI. There have been more than 100 surgical procedures developed for the management of SUI, and there is now adequate evidence that the MUS is associated with less pain, shorter hospitalization, faster return to usual activities, and reduced costs as compared with historic options that have been used to treat SUI over the past century. Full-length MUSs, both retropubic and transobturator, have been extensively studied, are safe and effective relative to other treatment options, and remain the leading treatment option and current criterion standard for SUI surgery. 13 More than 3 million MUS have been placed worldwide, and a recent survey indicates that these procedures are used by more than 99% of AUGS members. 14 
The FDA Has Clearly Stated That the Polypropylene MUS Is Safe and Effective in the Treatment of SUI
The MUS was not the subject of the 2011 FDA Safety Communication, ''Urogynecologic Surgical Mesh: Update on the Safety and Effectiveness of Vaginal Placement for Pelvic Organ Prolapse.'' 3 In this document, it was explicitly stated that, ''The FDA continues to evaluate the effects of using surgical mesh for the treatment of SUI and will report about that usage at a later date.'' In 2013, the FDA Web site stated clearly that, ''The safety and effectiveness of multi-incision slings is well established in clinical trials that followed patients for up to 1 year.'' 5
CONCLUSIONS
The polypropylene MUS has helped millions of women with SUI regain control of their lives by undergoing a simple outpatient procedure that allows them to return to daily life very quickly. With its acknowledged safety and efficacy, it has created an environment for a much larger number of women to have access to treatment. In the past, concerns over failure and invasiveness of surgery caused a substantial percent of incontinent women to live without treatment. One of the unintended consequences of this polypropylene mesh controversy has been to keep women from receiving any treatment of SUI. This procedure is probably the most important advancement in the treatment of SUI in the last 50 years and has the full support of our organizations, which are dedicated to improving the lives of women with urinary incontinence.
OUR ORGANIZATIONS
The AUGS, founded in 1979, is the premier nonprofit organization representing more than 1700 members including practicing physicians, nurse practitioners, physical therapists, nurses and health care professionals, and researchers from many disciplines, all dedicated to treating female pelvic floor disorders (pelvic organ prolapse and urinary incontinence). As the leader in female pelvic medicine and reconstructive surgery, AUGS promotes the highest quality patient care through excellence in education, research, and advocacy.
The SUFU is a nonprofit organization dedicated to improving the art and science of urology through basic and applied clinical research in urodynamics and neurourology, voiding function and dysfunction, female urology and pelvic floor dysfunction, and to disseminate and teach these concepts. It is the oldest professional organization dedicated to this field consisting of interested physicians, basic scientists, and other health care professionals, and it has grown to more than 500 members.
MIDURETHRAL SLING TASK FORCE
This position statement was drafted by members Charles Nager, Paul Tulikangas, and Dennis Miller from AUGS and Eric Rovner and Howard Goldman from SUFU.
